FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1978191819> ?p ?o ?g. }

• W1978191819 endingPage "314" @default.
• W1978191819 startingPage "304" @default.
• W1978191819 abstract "In people with type 2 diabetes mellitus (T2DM), the incretin effect is reduced, but the recent advent of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide (GLP)-1 agonists/analogues has enabled restoration of at least some of the function of the incretin system, with accompanying improvements in glycaemic control. Two GLP-1 receptor agonists/analogues are currently approved for the treatment of T2DM—exenatide (Byetta®, Eli Lilly & Co., Indianapolis, IN, US) and liraglutide (Victoza®, Novo Nordisk, Bagsvaerd, Denmark); a once-weekly formulation of exenatide (Bydureon®, Eli Lilly & Co.) has also been approved by the European Medicines Agency. The National Institute for Health and Clinical Excellence (NICE) has recently published guidance on the use of liraglutide in T2DM, based on evidence from the Liraglutide Effect and Action in Diabetes (LEAD) Phase III trial programme, which compared liraglutide with existing glucose-lowering therapies, such as exenatide and insulin glargine. The LEAD programme reported HbA1c reductions from 0.8 to 1.5% with liraglutide (1.2 and 1.8 mg), accompanied by low rates of hypoglycaemia and some weight loss; side effects were primarily gastrointestinal in nature (e.g. nausea and diarrhoea). Based on the findings of the LEAD studies and the NICE recommendation, liraglutide now represents an important therapy widely available in the UK for certain patient groups, including those with a body mass index (BMI) ≥35.0 kg/m2, and patients with a BMI <35 kg/m2 who are considered unsuitable for insulin and are failing to meet targets for glycaemic control with oral agents. NICE guidelines still suggest that most patients without considerable obesity (BMI <35 kg/m2) are probably best managed using insulin therapy. Evidence also suggests a future role for GLP-1 mimetics in combination with basal insulin." @default.
• W1978191819 created "2016-06-24" @default.
• W1978191819 creator A5023295361 @default.
• W1978191819 date "2011-12-22" @default.
• W1978191819 modified "2023-10-17" @default.
• W1978191819 title "The role of GLP‐1 mimetics and basal insulin analogues in type 2 diabetes mellitus: guidance from studies of liraglutide" @default.
• W1978191819 cites W1852436006 @default.
• W1978191819 cites W1965510020 @default.
• W1978191819 cites W1968865647 @default.
• W1978191819 cites W1977102586 @default.
• W1978191819 cites W1978953702 @default.
• W1978191819 cites W1982991923 @default.
• W1978191819 cites W1986331352 @default.
• W1978191819 cites W1987182389 @default.
• W1978191819 cites W1996796525 @default.
• W1978191819 cites W2004977380 @default.
• W1978191819 cites W2005038357 @default.
• W1978191819 cites W2025995365 @default.
• W1978191819 cites W2049798496 @default.
• W1978191819 cites W2050249722 @default.
• W1978191819 cites W2071835038 @default.
• W1978191819 cites W2078089300 @default.
• W1978191819 cites W2087707716 @default.
• W1978191819 cites W2098459806 @default.
• W1978191819 cites W2098674879 @default.
• W1978191819 cites W2101613382 @default.
• W1978191819 cites W2106824929 @default.
• W1978191819 cites W2118805427 @default.
• W1978191819 cites W2121414237 @default.
• W1978191819 cites W2122130517 @default.
• W1978191819 cites W2126781806 @default.
• W1978191819 cites W2127521907 @default.
• W1978191819 cites W2129512027 @default.
• W1978191819 cites W2131954113 @default.
• W1978191819 cites W2135692247 @default.
• W1978191819 cites W2137352234 @default.
• W1978191819 cites W2138290933 @default.
• W1978191819 cites W2139562487 @default.
• W1978191819 cites W2140952918 @default.
• W1978191819 cites W2153170671 @default.
• W1978191819 cites W2155568871 @default.
• W1978191819 cites W2160001758 @default.
• W1978191819 cites W2163502113 @default.
• W1978191819 cites W2164961795 @default.
• W1978191819 cites W2169274492 @default.
• W1978191819 cites W2170477895 @default.
• W1978191819 cites W2170606300 @default.
• W1978191819 cites W2171294019 @default.
• W1978191819 cites W2337454357 @default.
• W1978191819 cites W2769264260 @default.
• W1978191819 cites W4247470576 @default.
• W1978191819 doi "https://doi.org/10.1111/j.1463-1326.2011.01523.x" @default.
• W1978191819 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3488291" @default.
• W1978191819 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22051096" @default.
• W1978191819 hasPublicationYear "2011" @default.
• W1978191819 type Work @default.
• W1978191819 sameAs 1978191819 @default.
• W1978191819 citedByCount "46" @default.
• W1978191819 countsByYear W19781918192012 @default.
• W1978191819 countsByYear W19781918192013 @default.
• W1978191819 countsByYear W19781918192014 @default.
• W1978191819 countsByYear W19781918192015 @default.
• W1978191819 countsByYear W19781918192016 @default.
• W1978191819 countsByYear W19781918192017 @default.
• W1978191819 countsByYear W19781918192019 @default.
• W1978191819 countsByYear W19781918192020 @default.
• W1978191819 countsByYear W19781918192021 @default.
• W1978191819 countsByYear W19781918192022 @default.
• W1978191819 countsByYear W19781918192023 @default.
• W1978191819 crossrefType "journal-article" @default.
• W1978191819 hasAuthorship W1978191819A5023295361 @default.
• W1978191819 hasBestOaLocation W19781918191 @default.
• W1978191819 hasConcept C126322002 @default.
• W1978191819 hasConcept C134018914 @default.
• W1978191819 hasConcept C2776442814 @default.
• W1978191819 hasConcept C2777180221 @default.
• W1978191819 hasConcept C2778881409 @default.
• W1978191819 hasConcept C2779920387 @default.
• W1978191819 hasConcept C2780533449 @default.
• W1978191819 hasConcept C2781308992 @default.
• W1978191819 hasConcept C2910068830 @default.
• W1978191819 hasConcept C555293320 @default.
• W1978191819 hasConcept C71924100 @default.
• W1978191819 hasConcept C98274493 @default.
• W1978191819 hasConceptScore W1978191819C126322002 @default.
• W1978191819 hasConceptScore W1978191819C134018914 @default.
• W1978191819 hasConceptScore W1978191819C2776442814 @default.
• W1978191819 hasConceptScore W1978191819C2777180221 @default.
• W1978191819 hasConceptScore W1978191819C2778881409 @default.
• W1978191819 hasConceptScore W1978191819C2779920387 @default.
• W1978191819 hasConceptScore W1978191819C2780533449 @default.
• W1978191819 hasConceptScore W1978191819C2781308992 @default.
• W1978191819 hasConceptScore W1978191819C2910068830 @default.
• W1978191819 hasConceptScore W1978191819C555293320 @default.
• W1978191819 hasConceptScore W1978191819C71924100 @default.
• W1978191819 hasConceptScore W1978191819C98274493 @default.
• W1978191819 hasIssue "4" @default.
• W1978191819 hasLocation W19781918191 @default.

• next